

ATC codes: **L01CD01**

Indication	Malignant neoplasms of nasopharynx	ICD11 code: 2C3B.Z
INN	Paclitaxel	
Medicine type	Chemical agent	
List type	Complementary	
Formulations	Parenteral > General injections > IV: 6 mg per mL	
EML status history	First added in 2015 (TRS 994)	
Sex	All	
Age	Adolescents and adults	
Therapeutic alternatives	The recommendation is for this specific medicine	
Patent information	Patents have expired in most jurisdictions Read more about patents . 	

Tags

Cancer

Wikipedia

Paclitaxel 

DrugBank

Paclitaxel 

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for paclitaxel on the complementary list of the EML for use in treatment protocols for nasopharyngeal cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for nasopharyngeal cancer is attached.

Expert Committee report 

